Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hopes Rise For Approval Of Melanoma Drug Ipilimumab, With Positive Front-line Results

This article was originally published in The Pink Sheet Daily

Executive Summary

As Bristol-Myers' ipilimumab nears its March 26 PDUFA date for second-line melanoma, drug demonstrates good results in front-line study. Will the data sway regulators?
Advertisement

Related Content

Protecting The Blind: FDA, BMS Took Pains To Ensure Integrity Of Ongoing Yervoy Study
Protecting The Blind: FDA, BMS Took Pains To Ensure Integrity Of Ongoing Yervoy Study
Yervoy Approval Has Shifted Development Landscape For Melanoma
Yervoy Approval Has Shifted Development Landscape For Melanoma
Bristol Basks In Broad Ipilimumab Label, Sets High Price
Bristol Basks In Broad Ipilimumab Label, Sets High Price
Plexxikon CEO: Expect Business As Usual, After Whopping $805 Million Daiichi Buyout
Advisory Committee Review Will Test Whether One Trial Will Do The Trick For Bristol's Ipilimumab

Topics

Advertisement
UsernamePublicRestriction

Register

PS071987

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel